NBIX Neurocrine Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: NBIX

Price (delayed)

$150.82

Market cap

$15.33B

P/E Ratio

21.39

Dividend/share

N/A

EPS

$7.05

Enterprise value

$15.4B

?
Relative Growth: Rel. Growth: 98
Relative Strength: Rel. Strength: 44
Relative Valuation: Rel. Valuation: 69
Relative Profitability: Rel. Profitability: 98

Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients ...

Highlights
The company's net income has surged by 103% YoY and by 6% QoQ
NBIX's EPS has surged by 103% year-on-year and by 5% since the previous quarter
Neurocrine Biosciences's quick ratio has decreased by 49% YoY and by 42% from the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.neurocrine.com
Peers: RGEN RPRX ABBV PFE

Key stats

What are the main financial stats of NBIX

NBIX stock price

How has the Neurocrine Biosciences stock price performed over time
Intraday
-3.62%
1 week
-5.63%
1 month
-13.37%
1 year
14.59%
YTD
6.34%
QTD
-10.51%

Financial performance

How have Neurocrine Biosciences's revenue and profit performed over time
Revenue
$3.37B
Gross profit
$3.31B
Operating income
$794.8M
Net income
$705.5M
Gross margin
98%
Net margin
20.9%
The company's net income has surged by 103% YoY and by 6% QoQ
The operating income has surged by 61% year-on-year
The net margin has soared by 50% YoY but it is down by 3.2% QoQ
The gross profit has grown by 34% YoY and by 8% from the previous quarter

Price vs fundamentals

How does NBIX's price correlate with its fundamentals

Growth

What is Neurocrine Biosciences's growth rate over time

Valuation

What is Neurocrine Biosciences stock price valuation
NBIX P/E details
P/E
21.39
P/B
4.11
P/S
4.51
EV/EBIT
16.33
EV/EBITDA
15.3
EV/Sales
4.56
NBIX's EPS has surged by 103% year-on-year and by 5% since the previous quarter
The price to earnings (P/E) is 77% lower than the 5-year quarterly average of 93.4 and 19% lower than the last 4 quarters average of 26.4
The company's equity rose by 37% YoY and by 8% QoQ
NBIX's price to book (P/B) is 24% lower than its 5-year quarterly average of 5.4 and 7% lower than its last 4 quarters average of 4.4
Neurocrine Biosciences's revenue has increased by 34% YoY and by 9% QoQ
The stock's price to sales (P/S) is 27% less than its 5-year quarterly average of 6.2 and 8% less than its last 4 quarters average of 4.9

Efficiency

How efficient is Neurocrine Biosciences business performance
The company's return on invested capital has surged by 79% YoY and by 13% QoQ
The ROE has soared by 60% YoY but it has contracted by 2.3% from the previous quarter
Neurocrine Biosciences's return on assets has surged by 56% YoY but it has decreased by 2.6% QoQ
NBIX's return on sales is up by 33% year-on-year but it is down by 7% since the previous quarter

Dividends

What is NBIX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NBIX.

Financial health

How did Neurocrine Biosciences financials performed over time
Neurocrine Biosciences's quick ratio has decreased by 49% YoY and by 42% from the previous quarter
The company's current ratio fell by 42% YoY and by 36% QoQ
The debt is 89% lower than the equity
The company's equity rose by 37% YoY and by 8% QoQ
NBIX's debt to equity is down by 31% year-on-year and by 8% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.